Patient preference based phosphate binder therapy

Patient preference based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25073

Enrollment

Registered

2020-02-20

Start date

2020-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, end-stage renal disease

Interventions

Patients will use three different phosphate lowering agents consecutively in random order for 2 weeks per treatment: sevelamer, lanthanumcarbonate and sucroferric oxyhydroxide. After these trial perio

Eligibility

Inclusion criteria

Inclusion criteria: - Age = 18 years - Haemodialysis patients (since at least 3 months) - Necessity of phosphate binding therapy - Written informed consent

Exclusion criteria

Exclusion criteria: - Intolerance to one of three types of phosphate binders - Expected cessation of dialysis treatment within 6 months

Design outcomes

Primary

Measure	Time frame
Patient satisfaction with phosphate treatment measured with the Treatment Satisfaction Questionnaire for Medication (TSQM, version II).	—

Secondary

Measure	Time frame
Quality of life (SF-12), dialysis symptoms index (DSI), number of treatment switches, plasma phosphate , drug side effects questionnaire, drug adherence, serum PTH and Alkaline phosphatase.	—

Contacts

Public ContactT. Hoekstra

Amsterdam UMC, location AMC

t.hoekstra2@amsterdamumc.nl020-5667257

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)